Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 24, 2023

Rhea-AI Summary

Humacyte (Nasdaq: HUMA) will announce its financial results for Q4 and the year ended December 31, 2022, on March 24, 2023, at 8:00 AM ET. A webcast and conference call will follow to provide a corporate and financial update.

Humacyte focuses on developing bioengineered human tissues for various medical applications, notably in vascular treatments. Their human acellular vessels are in late-stage clinical trials and have received important FDA designations, including Regenerative Medicine Advanced Therapy (RMAT) and Fast Track.

Positive

• The human acellular vessels (HAVs) received FDA's Regenerative Medicine Advanced Therapy designation.
• HAVs are in late-stage trials for multiple vascular applications.
• Humacyte's products have received priority designation from the U.S. Secretary of Defense.

Negative

• None.

DURHAM, N.C., March 21, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, will release its financial results for the fourth quarter and year ended December 31, 2022, on Friday, March 24, 2023. Management will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update.

Title:	Humacyte Fourth Quarter and Year-End 2022 Financial Results and Corporate Update
Date:	Friday, March 24, 2023
Time:	8:00 AM ET
Conference Call Details:	Toll-Free: 1-877-704-4453 International: 1-201-389-0920 Conference ID#: 13736105
Webcast:	Webcast Link – Click Here

The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the investors section of the Company’s website for at least 30 days.

About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and complex tissue and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm HAV for arteriovenous (AV) access for performing hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation, and has also received FDA Fast Track designation. The HAV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com

Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com 

FAQ

When will Humacyte release its 2022 financial results?

Humacyte will release its 2022 financial results on March 24, 2023.

What is the purpose of Humacyte's upcoming conference call?

The conference call will provide a corporate and financial update following the release of Q4 and year-end results.

What is the significance of the FDA designations received by Humacyte?

The FDA designations, such as RMAT and Fast Track, indicate that Humacyte's products may be prioritized for approval, enhancing their market potential.

What clinical applications are being targeted with Humacyte's human acellular vessels?

Humacyte's human acellular vessels are targeting vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease.